VACCINEX INC

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

VCNX$1.41-61.4%Stored close · as of Dec 17, 2024

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss (Unaudited)

(in thousands, except share and per share data)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Revenue	$52	$20	$388	$570
Costs and expenses:
Research and development	3,165	4,355	10,412	13,217
General and administrative	1,439	1,499	5,324	5,250
Total costs and expenses	4,604	5,854	15,736	18,467
Loss from operations	(4,552)	(5,834)	(15,348)	(17,897)
Interest expense	-	-	-	(1)
Loss on settlement of warrants	(1,106)	-	(1,106)	-
Financing costs - warrant liabilities	-	-	(28)	-
Change in fair value of warrant liabilities	(71)	-	1,291	-
Change in fair value of derivative asset	-	-	(81)	-
Other income (expense), net	(3)	922	12	964
Loss before provision for income taxes	(5,732)	(4,912)	(15,260)	(16,934)
Provision for income taxes	-	-	-	-
Net loss attributable to Vaccinex, Inc. common stockholders	$(5,732)	$(4,912)	$(15,260)	$(16,934)
Comprehensive loss	$(5,732)	$(4,912)	$(15,260)	$(16,934)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	$(2.83)	$(15.25)	$(8.85)	$(59.95)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	2,026,920	322,153	1,724,088	282,467

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.